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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 204 (FGE.204): 
Consideration of genotoxicity data on representatives for 18 mono-
unsaturated, aliphatic, α,β-unsaturated ketones and precursors from 
chemical subgroup 1.2.1 of FGE.19 by EFSA
1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate the genotoxic potential of 18 flavouring substances 
from subgroup 1.2.1 of FGE.19 in the Flavouring Group Evaluation 204. The Flavour Industry 
provided additional genotoxicity studies for two representative substances, 4-methylpent-3-en-2-one 
[FL-no: 07.101] and 7-methyl-3-octenone-2 [FL-no: 07.177], which were evaluated in this FGE.204. 
Based on these new data, the Panel concluded that the flavouring substance [FL-no: 07.101] does not 
present a safety concern with respect to genotoxicity and accordingly it can be evaluated using the 
Procedure. On the contrary, the Panel could not conclude on the in vivo genotoxicity of [FL-no: 
07.177] and more appropriate in vivo genotoxicity tests, considering also first site of contact, should 
be performed. In addition, the substance 4-methyl-3-hepten-5-one [FL-no: 07.261] was now identified 
as a substance for which no representative substances could be identified in the present FGE, resulting 
in a need for additional data on the genotoxic potential of this flavouring substance. However, the 
Panel noted that the 2-methyl substituted α,-unsaturated aldehydes in FGE.201Rev1 can be 
considered as structurally related to [FL-no: 07.261]. Thus, the final conclusion on [FL-no: 07.261] 
will be drawn based on the outcome of the evaluation of FGE.201Rev1. 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Scientific Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission 
on the implications for human health of chemically defined flavouring substances used in or on 
foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
The present Flavouring Group Evaluation 204 (FGE.204), corresponding to subgroup 1.2.1 of 
FGE.19, concerns 16 mono-unsaturated, aliphatic, α,β-unsaturated ketones and two precursors for 
such ketones, oct-3-en-2-ol [FL-no: 02.102], oct-2-en-4-ol [FL-no: 02.193], pent-3-en-2-one [FL-no: 
07.044], 4-hexen-3-one [FL-no: 07.048], oct-2-en-4-one [FL-no: 07.082], 4-methylpent-3-en-2-one 
[FL-no: 07.101], hept-2-en-4-one [FL-no: 07.104], hept-3-en-2-one [FL-no: 07.105], 5-methylhex-3-
en-2-one [FL-no: 07.106], oct-3-en-2-one [FL-no: 07.107], dec-3-en-2-one [FL-no: 07.121], 5-
methylhept-2-en-4-one [FL-no: 07.139], 7-methyl-3-octenone-2 [FL-no: 07.177], non-2-en-4-one [FL-
no: 07.187], non-3-en-2-one [FL-no: 07.188], trans-6-methyl-3-hepten-2-one [FL-no: 07.244], 6-
methyl-3-hepten-2-one [FL-no: 07.258] and 4-methyl-3-hepten-5-one [FL-no: 07.261].  
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity and the data 
on genotoxicity previously available did not rule out the concern for genotoxicity for these 18 
flavouring substances. 
The Panel identified two substances in subgroup 1.2.1 which will represent the other substances in this 
subgroup (4-methylpent-3-en-2-one [FL-no: 07.101] and 7-methyl-3-octenone-2 [FL-no: 07.177]). For 
these two substances the Panel requested genotoxicity data according to the test strategy worked out 
by the Panel. 
According to the above requirements the Industry has submitted additional genotoxicity studies for 4-
methylpent-3-en-2-one and 7-methyl-3-octenone-2.  
Based on these new data, the Panel concluded that 4-methylpent-3-en-2-one and 7-methyl-3-octenone-
2 do not induce mutations in Salmonella typhimurium when tested up to toxic concentrations in the 
absence and in the presence of metabolic activation. 
4-Methylpent-3-en-2-one did not induce micronuclei in cultured human peripheral blood lymphocytes 
when tested up to toxic concentrations in both the absence and presence of S9-mix metabolism. 
Contrary, 7-methyl-3-octenone-2 induced micronuclei in human peripheral blood lymphocytes in the 
absence of S9-mix metabolism following 24-hour treatment. 
To clarify whether 7-methyl-3-octenone-2 was acting as a clastogen or an aneugen a fluorescence in 
situ hybridization (FISH) analysis was performed for 24 hours without S9-mix. Results obtained 
indicated that 7-methyloct-3-en-2-one is acting as a clastogenic compound. 
In order to determine whether positive results obtained in vitro for 7-methyl-3-octenone-2 could be 
confirmed in vivo, a bone marrow micronucleus test in rats was performed. 7-Methyl-3-octenone-2 did 
not induce micronuclei in bone marrow polychromatic erythrocytes (PCE). However, this outcome 
was accompanied by complete absence of clinical signs of toxicity in all animals, in all treatment 
groups. The observed very weak dose-related decrease in mean % PCE was considered by the Panel Flavouring Group Evaluation 204
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not indicative of bone marrow exposure. Therefore, the absence of induction of micronuclei in bone 
marrow erythrocytes does not necessarily reflect absence of clastogenicity in vivo of the test 
compound.  
On the basis of the available data, the Panel noted that no conclusions can be drawn about in vivo 
genotoxicity of 7-methyl-3-octenone-2 [FL-no: 07.177] and more appropriate in vivo genotoxicity 
tests, considering also first site of contact, should be performed. Alternatively, chemical analysis of the 
already available blood sample demonstrating target tissue exposure would also be suitable to make 
the results of the available micronucleus assay acceptable for the assessment of the hazard on 
genotoxic potential. 
For 4-methylpent-3-en-2-one [FL-no: 07.101], the data available showed that it did not induce 
mutations in bacteria or micronuclei in human peripheral blood lymphocytes, neither in the presence 
nor in the absence of rat liver S9-mix metabolic activation. Based on these findings, the Panel 
concluded that 4-methylpent-3-en-2-one does not present a safety concern with respect to genotoxicity 
and accordingly the flavouring substance can be evaluated using the Procedure. Since this substance is 
considered to be representative for itself only (“stand-alone”), as it is the only substance with a 
methyl-substituent on the -carbon atom of the double bond, this conclusion does not apply to any of 
the other candidate substances in this FGE. 
Subsequent to the publication of the list of representatives (EFSA, 2008bc), the Panel noted that 4-
methyl-3-hepten-5-one [FL-no: 07.261] differs structurally from all other substances in this subgroup 
owing to the presence of a methyl group in α-position of the double bond. Therefore, this substance is 
considered as a “stand alone” substance. The Panel noted that the 2-methyl substituted α,-unsaturated 
aldehydes in FGE.201Rev1 (EFSA, 2012h) can be considered as structurally related to [FL-no: 
07.261]. For the substances in FGE.201Rev1, 2-methylpent-2-enal [FL-no 05.090] has been selected 
as representative and further genotoxicity data were required. Thus, the final conclusion on [FL-no: 
07.261] will be drawn based on the outcome of the evaluation of FGE.201Rev1. Flavouring Group Evaluation 204
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/2012 (EC, 2012a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008b). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008b). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225). 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 
212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded 
that a genotoxic potential could be ruled out and accordingly these substances will be evaluated using Flavouring Group Evaluation 204
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the Procedure. For all, or some, of the substances in the remaining FGEs the genotoxic potential could 
not be ruled out (FGE.201. 203, 210, 212, 213, 216, 217 and 220).  
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA has worked out a list of 
representative substances for each subgroup (EFSA, 2008bc). Likewise, an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008bb).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.  
The Flavouring Industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity for subgroup 1.2.1 of FGE.19. 
TERMS OF REFERENCE 
The European Commission request the European Food Safety Authority to carry out a safety 
assessment on the following 18 substances: oct-3-en-2-ol [FL-no: 02.102], oct-2-en-4-ol [FL-no: 
02.193], pent-3-en-2-one [FL-no: 07.044], 4-hexen-3-one [FL-no: 07.048], oct-2-en-4-one [FL-no: 
07.082], 4-methylpent-3-en-2-one [FL-no: 07.101], hept-2-en-4-one [FL-no: 07.104], hept-3-en-2-one 
[FL-no: 07.105], 5-methylhex-3-en-2-one [FL-no: 07.106], oct-3-en-2-one [FL-no: 07.107], dec-3-en-
2-one [FL-no: 07.121], 5-methylhept-2-en-4-one [FL-no: 07.139], 7-methyl-3-octone-2 [FL-no: 
07.177], non-2-en-4-one [FL-no: 07.187], non-3-en-2-one [FL-no: 07.188], trans-6-methyl-3-hepten-
2-one [FL-no: 07.244], 6-methyl-3-hepten-2-one [FL-no: 07.258] and 4-methyl-3-hepten-5-one [FL-
no: 07.261], in accordance with Commission Regulation (EC) No 1565/2000. Flavouring Group Evaluation 204
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ASSESSMENT 
1.  Presentation of the substances in the Flavouring Group 
1.1.  Description 
The present Flavouring Group Evaluation 204 (FGE.204), corresponding to subgroup 1.2.1 of 
FGE.19, concerns 16 mono-unsaturated, aliphatic α,β-unsaturated ketones and two precursors for such 
ketones. The 18 substances under consideration in the present evaluation are listed in Table 1.  
Fifteen of the flavouring substances have previously been evaluated by the JECFA (JECFA, 2002c). A 
summary of their current evaluation status by the JECFA and the outcome of this consideration is 
presented in Table 2. 
The  α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008b) and the data on genotoxicity previously available did not rule out the concern for genotoxicity 
for these 18 flavouring substances. 
1.2.  Representative substances for subgroup 1.2.1 
In 2008, the Panel has identified two substances in subgroup 1.2.1 (EFSA, 2008bc) for which 
genotoxicity data according to the test strategy (EFSA, 2008bb) have been requested. These 
substances are listed in Table 1.1. 
TABLE  1.1 SUBSTANCES FOR WHICH GENOTOXICITY DATA HAVE BEEN REQUESTED FOR 
SUBGROUP 1.2.1 OF FGE.19 (EFSA, 2008BC) 
FL-no  
JECFA-no  
EU Register name   Structural formula   FEMA no  
CoE no  
CAS no  
07.101 
1131 
4-Methylpent-3-en-2-one  O 3368 
11853 
141-79-7 
07.177 
1135 
7-Methyl-3-octenone-2  
= 7-methyloct-3-en-2-one 
O 3868 
- 
33046-81-0 
 
Substance [FL-no: 07.101] was considered to be representative for itself only, since it is the only 
substance with a methyl-substituent on the  carbon atom of the double bond. The other substance, 
[FL-no: 07.177], was considred representative of the remaining substances of this FGE. 
Subsequent to the publication of the list of representative substances (EFSA, 2008bc), the Panel noted 
that 4-methyl-3-hepten-5-one [FL-no: 07.261] differs structurally from all other substances in this 
subgroup owing to the presence of a methyl group in α-position of the double bond. Therefore, this 
substance is considered as a “stand alone” substance. The Panel noted that the 2-methyl substituted 
α,-unsaturated aldehydes in FGE.201Rev1 (EFSA, 2012h) can be considered as structurally related to 
[FL-no: 07.261]. For the substances in FGE.201Rev1, 2-methylpent-2-enal [FL-no 05.090] has been 
selected as representative and further genotoxicity data were required. Thus, the final conclusion on 
[FL-no: 07.261] will be drawn based on the outcome of the evaluation of FGE.201Rev1. Flavouring Group Evaluation 204
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2.  Additionally submitted genotoxicity data on representative substances of subgroup 
1.2.1 
Introduction 
The Industry has submitted data concerning genotoxicity studies for the two representative substances 
for this subgroup (EFFA, 2012h) 
•  4-Methylpent-3-en-2-one [FL-no: 07.101] in vitro tests in bacteria and mammalian cell systems. 
•  7-Methyl-3-octenone-2 [FL-no: 07.177] in vitro tests in bacteria and mammalian cell systems and 
in vivo micronucleus test in rats. 
2.1.  In vitro data 
2.1.1.  Bacterial Reverse Mutation Assay 
Results of the in vitro studies described below are summarised in Table 3. 
4-Methylpent-3-en-2-one [FL-no: 07.101] 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 to assess the mutagenicity of 4-methylpent-3-en-2-one [FL-no: 07.101], both in the 
absence and presence of rat liver metabolizing system (S9-mix) in two experiments (Williams, 2009b). 
A preliminary range-finding cytotoxicity experiment using standard plate-incorporation methodology 
was conducted in strain TA100 only at concentrations of 1.6, 8, 40, 200, 1000 and 5000 μg/plate in the 
absence and presence of S9-mix, plus negative (solvent) and positive controls. Evidence of toxicity, in 
terms of a slight thinning of the background bacterial lawn, was observed only at the top concentration 
in the presence of S9-mix. The data from the range-finding experiment were considered acceptable for 
mutation assessment, and therefore, to complete the first experiment, the remaining four strains were 
tested at the same concentrations both in the presence and absence of S9-mix using the same 
methodology. No evidence of toxicity was observed in these strains, and no increases in reverse 
mutants relative to the vehicle control were observed. 
In a second experiment, 4-methylpent-3-en-2-one was tested in all five S. typhimurium strains with 
and without S9-mix, using a narrowed concentration range of 156.25, 312.5, 625, 1250, 2500 and 
5000 μg/plate. A pre-incubation step was also included when the chemical was tested in the presence 
of S9-mix. Following these treatments, evidence of toxicity in the form of a slight thinning of the 
background bacterial lawn was observed at the highest concentrations (2500 and 5000 μg/plate) in all 
strains in the presence of S9-mix and in strain TA102 in the absence of S9-mix. A small increase (1.5-
fold) in TA1535 revertants was seen at the higest concentration in the absence of S9-mix that was 
significant at p < 0.05, but this small increase was not seen in the first experiment at similar 
concentrations and was considered by the study authors to be due to chance. No increases in revertant 
numbers were observed for the other strains and treatment conditions. 
Based on the above results the Panel concluded that 4-methylpent-3-en-2-one [FL-no: 07.101] did not 
induce mutations in five strains of S. typhimurium when tested up to toxic concentrations in the 
absence and in the presence of metabolic activation (Williams, 2009b). 
7-methyl-3-octenone-2 [FL-no: 07.177] 
Previously, an Ames assay had been performed with 7-methyl-3-octenone-2 [FL-no: 07.177] in S. 
typhimurium  strains TA98, TA100, TA1535, TA1537 and TA1538 with and without S9-mix 
metabolic activation at concentrations ranging from 15 - 5000 μg/plate. The test compound showed 
toxicity in terms of reduction of bacterial lawn at dose-levels of 1500 μg/plate and higher, both in the Flavouring Group Evaluation 204
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absence and presence of S9-mix. No significant increases in the frequencies of revertant colonies were 
observed in any of the tester strains employed, at any dose-level assayed with and without metabolic 
activation (Thompson, 1996a). To supplement these results and thus provide data for a battery of test 
strains consistent with the requirements for current regulatory guidelines (OECD TG 471, 1997), a 
new Ames study (standard plate incorporation method) using the S. typhimurium tester strain TA102 
at concentrations of 1.6, 8, 40, 200, 1000 and 5000 μg/plate with and without S9-mix was performed 
with 7-methyl-3-octenone-2 (Ballantyne, 2011b). Evidence of toxicity in the presence and absence of 
S9-mix was observed at the highest concentration tested. No increase in reverse mutant counts 
following treatments with 7-methyl-3-octenone-2 compared with the vehicle control were observed at 
any dose-level assayed. In a second experiment, 7-methyl-3-octenone-2 was assayed in strain TA102 
with and without S9-mix and a narrowed concentration range of 51.2, 128, 320, 800, 2000 and 5000 
μg/plate. In the presence of S9-mix, a pre-incubation step was also included. Following 7-methyl-3-
octenone-2 treatment, evidence of toxicity was observed in the presence and absence of S9-mix, on 
plates treated at 2000 or 5000 µg/plate. Treatment of strain TA102 with 7-methyl-3-octenone-2, with 
and without S9-mix, did not induce any statistically significant increase in revertant numbers (data 
were analysed at the 1 % level using Dunnett’s) at the tested concentrations (Ballantyne, 2011b). 
Taken together with the data of Thompson (1996), the Panel concluded that 7-methyl-3-octenone-2 
[FL-no: 07.177] did not induce mutations in six strains of S. typhimurium when tested up to toxic 
concentrations in the absence and in the presence of metabolic activation (Thompson, 1996a; 
Ballantyne, 2011b). 
2.1.2.  In vitro micronucleus assays  
Results of the studies described below are summarised in Table 3. 
4-Methylpent-3-en-2-one [FL-no: 07.101] 
4-Methylpent-3-en-2-one was tested for the induction of chromosome damage and potential aneugenic 
effects in mammalian cells in vitro by examining the effect on the frequency of micronuclei in 
cultured human peripheral blood lymphocytes, treated in the absence and presence of rat liver 
metabolizing system (S9-mix) (Stone, 2011). 
A preliminary range-finding experiment was conducted with and without S9-mix in order to determine 
the effect of the test substance upon Replication Index (RI), which was used as a basis for choosing a 
range of concentrations to be evaluated in the main study. 4-Methylpent-3-en-2-one was added to cell 
cultures after 48 hours from culture initiation (stimulation by phytohaemagglutinin PHA), either for 3 
hours in the absence or presence of S9-mix, or for 24 hours in the absence of S9-mix. Micronuclei 
were analyzed at multiple concentrations for each treatment group. For the 3-hour treatment (3 + 21 
hours recovery) the concentrations were 0, 600, 800 and 981.4 μg/ml (without S9-mix) and 0, 200, 
400, 800, 981.4 μg/ml (with S9-mix). The levels of cytotoxicity (reduction in RI) induced at the top 
concentrations were 22 % and 54 % in the absence and presence of S9-mix, respectively. Although the 
recommended range of toxicity (50 - 60 %) was not reached in the absence of S9-mix, the top 
concentration of 981.4 μg/ml was equivalent to 10 mM, which is the required upper limit for a non-
toxic substance. For 24-hour treatment without S9-mix the concentrations were 0, 100, 200, 275 and 
300 μg/ml and the level of cytotoxicity (reduction in RI) at the top concentration reached 62 %, which 
exceeded the target (50 - 60 %) range. One thousand binucleate cells per culture from two replicate 
cultures per concentration were scored for micronuclei.  
Treatment of cells with 4-methylpent-3-en-2-one for 3 hours in the presence of S9-mix resulted in 
statistically significant (p ≤ 0.05) increases in MNBN frequency compared to the concurrent vehicle 
control at the highest concentration analysed (981.4 μg/mL). However, only one replicate culture in 
the assay resulted in MNBN cell frequencies outside of the normal range and the authors considered 
this result as equivocal. Therefore a confirmatory experiment was performed with 4-methylpent-3-en-Flavouring Group Evaluation 204
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2-one at concentrations of 0, 100, 200, 400 and 500 μg/ml for 3 hours with S9-mix. The lower 
concentrations chosen in the second experiment were on the basis of an unexplained shift in toxicity, 
but the concentrations selected for analysis in this experiment gave comparable toxicity to those 
selected in the prior experiment under this treatment condition, and 58 % cytotoxicity (determined as 
reduction in RI) was achieved at the top concentration. These treatments resulted in frequencies of 
MNBN cells that were similar to concurrent controls and there were no significant differences.  
Considering that the significant increase in MNBN cell frequencies in the first experiment were not 
reproduced in the second one, the Panel concluded that 4-methylpent-3-en-2-one [FL-no: 07.101] did 
not induce micronuclei in cultured human peripheral blood lymphocytes when tested up to toxic 
concentrations in both the absence and presence of S9-mix metabolism (Stone, 2011). 
7-Methyl-3-octenone-2 [FL-no: 07.177] 
7-Methyl-3-octenone-2 [FL-no: 07.177] was tested in an in vitro micronucleus assay in cultured 
human peripheral blood lymphocytes treated in the absence and presence of rat liver metabolizing 
system (S9-mix) (Lloyd, 2009d). 7-Methyl-3-octenone-2 [FL-no: 07.177] was added at 48 hours 
following mitogen stimulation by PHA either for 3 hours in the absence or presence of S9-mix, or for 
24 hours in the absence of S9-mix. The test substance concentrations for micronucleus analysis were 
selected by evaluating the effect of 7-methyl-3-octenone-2 on the Replication Index (RI). In the main 
experiment, micronuclei were analysed at multiple concentrations for each treatment group.  
For 3-hour treatment without S9-mix the concentrations were 5, 10 and 15 μg/ml, for 3-hour treatment 
with S9-mix the concentrations were 30, 40 and 60 μg/ml, and for 24-hour treatment without S9-mix 
the concentrations were 2, 4 and 6 μg/ml. The levels of cytotoxicity (reduction in RI) at the top 
concentrations reached 45 % (in the 3 + 21 hours treatment without S9-mix), 58 % (in the 3 + 21 hours 
treatment with S9-mix) and 59 % (in the 24 hours treatment without S9-mix). One thousand binucleate 
cells per culture from two replicate cultures per concentration were scored for micronuclei.  
Treatment of cells with 7-methyl-3-octenone-2 for 3 + 21 hours resulted in frequencies of MNBN cells 
that were significantly higher (p ≤ 0.05) than those observed in concurrent vehicle controls at the 
highest concentrations analysed in the absence and presence of S9-mix (15.00 μg/mL and 60.00 
μg/mL, respectively). However, the MNBN cell frequencies in all treated cultures in the absence and 
presence of S9-mix fell within historical range values for vehicle control. These observations were not 
considered biologically relevant by the authors of the study report. 
For the 24-hour treatment, at the two highest concentrations (4.0 and 6.0 μg/mL), the frequencies of 
MNBN cells were significantly higher (p ≤ 0.05, p ≤ 0.001, respectively) than those observed in the 
concurrent vehicle control (0.2 %). The MNBN cell frequencies in those cultures treated with the 
highest concentration exceeded the normal ranges and therefore this was considered to be a positive 
result. 
Therefore, the Panel concluded that 7-methyl-3-octenone-2 induced micronuclei in cultured peripheral 
blood lymphocytes when tested up to toxic concentrations for 24 hours in the absence of S9-mix 
(Lloyd, 2009d). 
In order to determine whether 7-methyl-3-octenone-2 was acting as a clastogen or an aneugen, a 
follow-up study was performed using fluorescence in situ hybridization (FISH) analysis (Lloyd, 
2010c). Micronuclei were analyzed at multiple concentrations separated by narrow intervals, which 
were based on the toxicity displayed in a preliminary range-finding experiment for 24 hours without 
S9-mix treatment. The concentrations analyzed were 5.5, 6.0, 7.0 and 8.0 μg/ml. The levels of 
cytotoxicity (reduction in replication index, RI) was concentration-dependent and, at the top 
concentration, reached 56 %.  Flavouring Group Evaluation 204
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All concentrations of 7-methyl-3-octenone-2 (5.5, 6.0, 7.0 and 8.0 μg/ml) resulted in significant 
increases of MNBN cells (p ≤ 0.05, p ≤ 0.01, p ≤ 0.01 and p ≤ 0.001, respectively) relative to vehicle 
controls. The increase of MNBN cells ranged from 2.3 to 4.7 fold greater than the concurrent control, 
and exceeded the historical control range at the highest concentration tested (1.4 % mean MNBN cell 
frequency vs. 0.1 - 0.9 % historical control range).  
The FISH analyses, with a fluorochrome-labelled pan-centromeric human DNA probe specific for all 
human chromosomes, to identify micronuclei containing centromeres, were performed on slides 
generated from vehicle control, 7-methyl-3-octenone-2 along with a clastogenic positive control 
(Mitomycin C) and an aneugenic positive control (Vinblastine). 
Treatment with 7 and 8 μg/ml 7-methyl-3-octenone-2 resulted in 20 % and 18 % centromere-positive 
micronuclei, respectively compared to 46 % centromere-positive micronuclei for the vehicle control, 9 
% for the reference clastogen and 84 % for the reference aneugen. On this basis, the authors concluded 
that the induction of increased MNBN cell frequency is primarily a result of chromosome breakage 
rather than chromosome loss following treatment of cultured peripheral blood lymphocytes with 7-
methyl-3-octen-2-one for 24 hours in the absence of S9-mix (Lloyd, 2010c). Based on these results, 
the Panel agreed that 7-methyl-3-octenone-2 [FL-no: 07.177] is an in vitro clastogen for human 
lymphocytes. 
2.2.  In vivo data 
Considering the results from the in vitro micronucleus assays, it was concluded that 7-methyl-3-
octenone-2 [FL-no: 07.177] was an in vitro clastogen for human lymphocytes, and therefore it was 
decided that it was most appropriate to carry out an in vivo micronucleus assay to determine whether 
the results obtained in the in vitro micronucleus assays could be confirmed in vivo. Therefore, groups 
of Han-Wistar rats were administered 7-methyl-3-octenone-2 via oral gavage and the induction of 
micronuclei in the polychromatic erythrocyte (PCE) of the bone marrow was examined. 
As no substantial difference in toxicity was observed between males and females in the range-finding 
experiment, male rats only were used in the micronucleus experiment. Groups of male (6 
animals/group) rats were administered 7-methyl-3-octenone-2 by oral gavage at 500, 1000 and 2000 
mg/kg bw/day on 2 occasions 24 hours apart (Table 4). An additional satellite group of animals was 
dosed at 2000 mg/kg bw/day to facilitate later blood analysis if desired. Animals were sampled 24 
hours after the final administration, thus enabling examination of cells exposed to the test article over 
a period of 24 to 48 hours prior to sampling. No clinical signs of toxicity were observed in any 
animals in any main treatment groups. In the satellite group, animals showed decreased signs of 
activity on day 2 at 0.5 and 1.0 hours post dose.  
Rats treated with 7-methyl-3-octenone-2 exhibited a very weak but dose-related decrease in mean % 
polychromatic erythrocytes (PCE) was however comparable with the historical control data for this 
experiment at the testing laboratory. No statistically significant increase in micronucleus frequency 
was observed for any of the groups receiving the test substance, compared to the concurrent vehicle 
control (Table 5). On this basis, the authors concluded that 7-methyl-3-octenone-2 did not induce 
micronuclei in the polychromatic erythrocytes of the bone marrow of male rats treated up to 2000 
mg/kg/day (Henderson, 2011). 
Results of the in vivo studies described above are summarised in Table 4 and 5. 
2.3.  Discussion of Mutagenicity/Genotoxicity Data 
The two representative substances, 4-methylpent-3-en-2-one [FL-no: 07.101] and 7-methyl-3-
octenone-2 [FL-no: 07.177], are both considered negative in the Ames test with S. typhimurium tester 
strains consistent with the requirements for current regulatory guidelines. Statistically significant Flavouring Group Evaluation 204
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increase in the number of revertant colonies observed in tester strain TA1535 in the absence of S9-mix 
metabolism in one experiment following treatment with 4-methylpent-3-en-2-one are judged not 
biologically relevant, since they were not reproduced in the second experiment (Williams, 2009b; 
Ballantyne, 2011b).  
Investigations at chromosome and genome levels in mammalian cells in vitro showed that 4-
methylpent-3-en-2-one induced a small but statistically significant increase in the frequency of 
micronucleated binucleate cells (MNBN) only in the presence of S9-mix metabolism following a three 
hour treatment at the highest concentration tested (981.4 µg/ml). However, only one replicate culture 
fell outside the historical vehicle control range values. Following additional scoring of 2000 
erythrocytes, the resulting MNBN frequencies, although still significantly higher than concurrent 
vehicle control, lied within historical control range values. In a second confirmatory experiment (3-
hour treatment in the presence of S9-mix) performed at concentrations lower than concentrations used 
in the previous experiment, due to an unexplained shift of toxicity (comparable toxicity to those 
observed in the first experiment, but at lower concentrations), no significant increase in MNBN 
frequencies was observed. Based on these results the Panel concluded that 4-methylpent-3-en-2-one 
did not induce micronuclei in human peripheral blood lymphocytes, both in the absence and presence 
of rat liver S9-mix metabolism. On the contrary, 7-methyl-3-octenone-2 induced statistically 
significant increases in MNBN following the 3-hour treatment both in the absence and presence of S9-
mix at the highest concentrations tested. However, the observed increase of MNBN cell frequencies 
fell within relevant historical control values. In the 24-hour treatment in the absence of S9-mix, 7-
methyl-3-octenone-2 induced statistically significant increase in MNBN cell frequencies at the two 
highest concentrations, selected for scoring and exceeded the historical control range values (Lloyd 
2009d). Therefore, the Panel concluded that 7-methyl-3-octenone-2 induces micronuclei in human 
peripheral blood lymphocytes in vitro in the absence of S9-mix metabolism following 24-hour 
treatment. 
To determine whether 7-methyl-3-octenone-2 was acting as a clastogen or an aneugen, a follow up 
study was performed, in the absence of S9-mix, following a treatment of 24 hours at similar 
concentrations used in the previous study (Lloyd 2010c). FISH analysis was performed to identify 
micronuclei containing centromeres. Results obtained confirmed previous findings and clearly 
indicated that 7-methyl-3-octenone-2 is acting as a clastogenic compound. In order to determine 
whether positive results obtained in vitro for 7-methyl-3-octenone-2 could be confirmed in vivo, a 
bone marrow micronucleus test in rats treated in vivo was performed.  
The test substance 7-methyl-3-octenone-2 administered by oral gavage at doses of 500, 1000 and 2000 
mg/kg bw on two occasions with 24 hours apart to Han-Wistar rats did not prove to induce 
micronuclei in bone marrow polychromatic erythrocytes (PCE). However, this outcome was 
accompanied by complete absence of clinical signs of toxicity in any animal, in any treatment group. 
The observed very weak dose-related decreases in mean % PCE was considered by the Panel not 
indicative of bone marrow exposure as suggested by the author of the study report, since group mean 
values of % PCE fall within observed historical range values at 95 % confidence interval as reported 
in the study report (Henderson, 2012) and displayed in Table 5. These findings do not allow to 
conclude a bone marrow exposure and therefore absence of induction of micronuclei in bone marrow 
erythrocytes does not necessarily reflect absence of clastogenicity in vivo of the test substance. Blood 
was appropriately collected and processed but, as stated in the study report, it was not analysed to 
measure the plasma level of 7-methyl-3-octenone-2 due to the lack of a bioanalytical method. The 
direct reactivity of the test substance evinced by clastogenicity induced in vitro, (in the absence of S9-
mix metabolism) indicates a reduced systemic availability of the test substance. 
CONCLUSIONS 
On the basis of the available data, the Panel noted that no conclusions can be drawn about in vivo 
genotoxicity of 7-methyl-3-octenone-2 [FL-no: 07.177] and more appropriate in vivo genotoxicity Flavouring Group Evaluation 204
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tests, considering also first site of contact, should be performed. Alternatively, chemical analysis of the 
already available blood samples demonstrating target tissue exposure would also be suitable to make 
the results of the available micronucleus assay acceptable for the assessment of the genotoxic 
potential. 
For 4-methylpent-3-en-2-one [FL-no: 07.101], the data available showed that it did not induce 
mutations in bacteria or micronuclei in human peripheral blood lymphocytes, neither in the presence 
nor in the absence of rat liver S9-mix metabolic activation. Based on these findings, the Panel 
concluded that 4-methylpent-3-en-2-one does not present a safety concern with respect to genotoxicity 
and accordingly the flavouring substance can be evaluated using the Procedure. Since this substance is 
considered to be representative for itself only (“stand-alone”), as it is the only substance with a 
methyl-substituent on the -carbon atom of the double bond, this conclusion does not apply to any of 
the other candidate substances in this FGE. 
Subsequent to the publication of the list of representatives (EFSA, 2008bc), the Panel noted that 4-
methyl-3-hepten-5-one [FL-no: 07.261] differs structurally from all others in this subgroup owing to 
the presence of a methyl group in α-position of the double bond. Therefore, this substance is 
considered as a “stand alone” substance. The Panel noted that the 2-methyl substituted α,-unsaturated 
aldehydes in FGE.201Rev1 (EFSA, 2012h) can be considered as structurally related to [FL-no: 
07.261]. For the substances in FGE.201Rev1, 2-methylpent-2-enal [FL-no 05.090] has been selected 
as representative and further genotoxicity data were required. Thus, the final conclusion on [FL-no: 
07.261] will be drawn based on the outcome of the evaluation of FGE.201Rev1. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 204 (JECFA, 2002D)  
Table 1: Specification Summary of the Substances in the present group (JECFA, 2002d) 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.102 
1140 
Oct-3-en-2-ol 6) 
OH 
3602 
 
76649-14-4 
Liquid 
C8H16O 
128.22 
Insoluble 
Miscible 
73-76 (13 hPa) 
 
IR NMR MS 
98 % 
1.422-1.428 
0.826-0.836 
02.193 
1141 
Oct-2-en-4-ol 6) 
OH  
3888 
 
4798-61-2 
Liquid 
C8H16O 
128.22 
Insoluble 
50% Soluble in ethanol 
 
 
IR NMR MS 
95 % 
1.438-1.442 
0.830-0.838 
07.044 
1124 
Pent-3-en-2-one 6) 
O
 
3417 
666 
625-33-2 
Liquid 
C5H8O 
84.12 
Slightly soluble 
Miscible 
122 
 
NMR 
98 % 
1.433-1.437 
0.860-0.865 
07.048 
1125 
4-Hexen-3-one 6) 
O
 
3352 
718 
2497-21-4 
Liquid 
C6H10O 
98.15 
Slightly soluble 
Miscible 
93 (195 hPa) 
 
NMR 
98 % 
1.437-1.443 
0.855-0.861 
07.082 
1129 
Oct-2-en-4-one 6) 
O
 
3603 
2313 
4643-27-0 
Liquid 
C8H14O 
126.20 
Insoluble 
Miscible 
81 (26-27 hPa) 
 
IR NMR 
96 % 
1.440-1.446 
0.835-0.842 
07.101 
1131 
4-Methylpent-3-en-2-one 
O
 
3368 
11853 
141-79-7 
Liquid 
C6H10O 
98.14 
Slightly soluble 
Miscible 
126.76 
 
NMR 
95 % 
1.442-1.447 
0.862-0.868 
07.104 
1126 
Hept-2-en-4-one 6) 
O
 
3399 
11093 
4643-25-8 
Liquid 
C7H12O 
112.17 
Slightly soluble 
Miscible 
156-157 
 
IR NMR 
99 % 
1.440-1.445 
0.845-0.852 
07.105 
1127 
Hept-3-en-2-one 6) 
O
 
3400 
11094 
1119-44-4 
Liquid 
C7H12O 
112.17 
Slightly soluble 
Miscible 
162 
 
NMR 
96 % 
1.439-1.448 
0.841-0.847 
07.106 
1132 
5-Methylhex-3-en-2-one 6) 
O
 
3409 
11149 
5166-53-0 
Liquid 
C7H12O 
112.17 
Insoluble 
Miscible 
77.5 (65 hPa) 
 
NMR 
99 % 
1.437-1.441 
0.838-0.843 
07.107 
1128 
Oct-3-en-2-one 6) 
O
 
3416 
11170 
1669-44-9 
Liquid 
C8H14O 
126.19 
Insoluble 
Miscible 
75-79 (26 hPa) 
 
NMR 
94 % 
1.445-1.449 
0.834-0.839 Flavouring Group Evaluation 204
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Table 1: Specification Summary of the Substances in the present group (JECFA, 2002d) 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
07.121 
1130 
Dec-3-en-2-one 6) 
O
 
3532 
11751 
10519-33-2 
Liquid 
C10H18O 
154.25 
Almost insoluble 
Miscible 
125-126 
 
NMR 
95 % 
1.446-1.452 
0.809-0.813 
07.139 
1133 
5-Methylhept-2-en-4-one  6) 
O
 
3761 
 
81925-81-7 
Liquid 
C8H14O 
126.19 
Slightly soluble 
Miscible 
86-87 (78 hPa) 
 
NMR 
98 % 
1.440-1.445 
0.845-0.852 
07.177 
1135 
7-Methyl-3-octenone-2 6) 
O
 
3868 
 
33046-81-0 
Liquid 
C9H16O 
140.2 
Slightly soluble 
Miscible 
198 
 
IR NMR MS 
94 % 
1.446-1.451 
0.838-0.847 
07.187 
 
Non-2-en-4-one  6) 
O
 
 
11162 
32064-72-5 
Liquid 
C9H16O 
140.22 
Insoluble 
Freely soluble 
82 (27 hPa) 
 
MS 
95 % 
1.422-1.428 
0.823-0.829 
07.188 
1136 
Non-3-en-2-one 6) 
O
 
3955 
11163 
14309-57-0 
Liquid 
C9H16O 
140.22 
Insoluble 
Miscible 
198 
 
IR MS 
95 % 
1.443-1.452 
0.843-0.846 
07.244 
1138 
trans-6-Methyl-3-hepten-2-one  
O
 
4001 
 
20859-10-3 
Liquid 
C8H14O 
126.2 
Insoluble 
Miscible 
178-170 
 
NMR 
96 % 
1.438-1.447 
0.840-0.850 
07.258 
 
6-Methyl-3-hepten-2-one 6) 
O
 
 
 
2009-74-7 
Liquid 
C8H14O 
126.20 
Practically insoluble or 
insoluble 
Freely soluble 
179 
 
MS 
96 % 
1.436-1.442 
0.842-0.848 
07.261 
 
4-Methyl-3-hepten-5-one 6) 
O  
 
 
22319-31-9 
Liquid 
C8H14O 
126.20 
Insoluble 
Freely soluble 
179 
 
MS 
96.12 % 
1.442-1.462 
0.851-0.871 
1)  Solubility in water, if not otherwise stated. 
2)  Solubility in 95 % ethanol, if not otherwise stated. 
3)  At 1013.25 hPa, if not otherwise stated. 
4)  At 20°C, if not otherwise stated. 
5)  At 25°C, if not otherwise stated. 
6)  Stereoisomeric composition not specified. 
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TABLE 2: CURRENT SAFETY EVALUATION STATUS APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
(JECFA, 2002C) 
Table 2: Summary of Safety Evaluation of the JECFA substances in the present group (JECFA, 2002c) 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 1) 
US MSDI (g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
02.102 
1140 
Oct-3-en-2-ol 
OH
1.2 
ND 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
02.193 
1141 
Oct-2-en-4-ol 
OH
ND 
ND 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.044 
1124 
Pent-3-en-2-one 
O 0.26 
ND 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.048 
1125 
4-Hexen-3-one 
O 13 
1 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.104 
1126 
Hept-2-en-4-one 
O 0.012 
ND 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.139 
1133 
5-Methylhept-2-en-4-one 
O 5.8 
1 
Class I 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.082 
1129 
Oct-2-en-4-one 
O 0.85 
3 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.101 
1131 
4-Methylpent-3-en-2-one 
O
 
0.34 
ND 
Class II 
A3: Intake below threshold 
4)  No safety concern with respect to 
genotoxicity. To be evaluated 
through the Procedure. 
07.105 
1127 
Hept-3-en-2-one 
O 0.16 
0.07 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.106 
1132 
5-Methylhex-3-en-2-one 
O ND 
0.1 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.107 
1128 
Oct-3-en-2-one 
O 0.63 
1 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.121 
1130 
Dec-3-en-2-one 
O 0.012 
ND 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.177 
1135 
7-Methyl-3-octenone-2 
O ND 
2 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.188 
1136 
Non-3-en-2-one 
O 13 
13 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required Flavouring Group Evaluation 204
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Table 2: Summary of Safety Evaluation of the JECFA substances in the present group (JECFA, 2002c) 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 1) 
US MSDI (g/capita/day) 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
07.244 
1138 
trans-6-Methyl-3-hepten-2-one 
O 3.4 
3 
Class II 
A3: Intake below threshold 
4)  Evaluated in FGE.204, additional 
genotoxicity data required 
07.187 
 
Non-2-en-4-one 
O 0.0012 
 
Class II 
No evaluation 
Not evaluated by the JECFA  Evaluated in FGE.204, additional 
genotoxicity data required 
07.258 
 
6-Methyl-3-hepten-2-one 
O 0.061 
 
Class II 
No evaluation 
Not evaluated by the JECFA  Evaluated in FGE.204, additional 
genotoxicity data required 
07.261 
 
4-Methyl-3-hepten-5-one 
O
 
 
 
No evaluation 
Not evaluated by the JECFA  Evaluated in FGE.204, additional 
genotoxicity data required 
1)  EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
2)  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3)  Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
4)  No safety concern based on intake calculated by the MSDI approach of the named compound. 
5)  Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND Not  determined. Flavouring Group Evaluation 204
 
 
18  EFSA Journal 2012;10(12):2992 
TABLE 3: GENOTOXICITY (IN VITRO)  
Table 3: Summary of Additionally Submitted Genotoxicity Data on the Representative Substance of Subgroup 1.2.1 
FL-no Chemical  Name  Test System in vitro   Test Object   Concentrations of Substance and 
Test Conditions 
Result   Reference   Comments  
[07.101] 4-Methylpent-3-en-2-one Reverse  Mutation  S.typhimurium 
TA98, TA100, TA102, 
TA1535 and TA1537 
1.6 - 5000 μg/plate [1]  Negative  (Williams, 
2009b) 
Valid. 
Study design complies with current 
recommendations. 
156.25 - 5000 μg/plate [1,2]  Negative 
Micronucleus Assay  Human peripheral blood 
lymphocytes 
600 - 981.4 μg/ml [3]  Negative  (Stone, 2011)  Valid. 
Complies with OECD Guideline 487. 
200 - 981.4 μg/ml [4]  Negative 
100 - 500 μg/ml [4]  Negative 
100 - 300 μg/ml [5]  Negative 
[07.177] 7-methyl-3-octenone-2  Reverse  Mutation  S.typhimurium 
TA102 
1.6 - 5000 μg/plate [1]  Negative  (Ballantyne, 
2011b) 
Valid. 
Studies combined comply with current 
recommendations. 
51.2 - 5000 μg/plate [1,2]  Negative 
S.typhimurium 
TA98, TA100, TA1535, 
TA1537, and TA1538 
15 - 5000 μg/plate [1]  Negative  (Thompson, 
1996a) 
Micronucleus Assay  Human peripheral Blood 
lymphocytes 
5 - 15 μg/ml [3]  Equivocal  (Lloyd, 2009d)  Valid. 
Testing strategies including FISH analyses for 
determination of potential clastogenicity or 
aneugenicity Comply with OECD Guideline 487.  30 - 60 μg/ml [4]  Equivocal 
2 - 6 μg/ml [5]  Positive 
5.5 - 8 μg/ml [5]  Positive  (Lloyd, 2010c) 
Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). Flavouring Group Evaluation 204
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Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
 
[1]  With and without S9-mix metabolic activation 
[2]  Assay modified with pre-incubation in the presence of S9-mix. 
[3]  Without metabolic activation, 3 hours treatment + 21 hours recovery 
[4]  With metabolic activation, 3 hours treatment + 21 hours recovery 
[5]  Without metabolic activation, 24 hours + 0 hours recovery Flavouring Group Evaluation 204
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TABLE 4: GENOTOXICITY (IN VIVO)  
Table 4: Summary of Additionally Submitted In Vivo Genotoxicity Data on 7-Methyl-3-octenone-2 
FL-no Chemical  Name  Test System in vivo  Test Object / Sex 
No per group / groups 
Route   Concentrations of Substance   Result  Reference   Comments  
[07.177] 7-methyl-3-octenone-2  Micronucleus Assay  Male Han Wister rats / 6 
animals/group 
Gavage on 2 occasions 
24 hours apart 
0, 500, 1000 and 2000 mg/kg 
bw/day 
Negativ
e 
(Henderson, 2011)  Valid. 
Complies with OECD Guideline 474. 
Althoug the study was performed at the 
maximum recommended highest dose-level 
(2000 mg/kg) no clear indication of toxicity 
was observed indicating that test substance 
might not have been sistemically available. 
This is also supported by positive findings 
observed in the in vitro micronucleus assay 
in the absence of S9 metabolism which 
indicates a direct reactivity of test 
compound. 
Validity of genotoxicity studies: 
Valid. 
Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and / or limited documentation). 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system). 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language). 
 Flavouring Group Evaluation 204
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TABLE 5: COMPARISON OF TEST GROUPS PCE (%) AND HISTORICAL CONTROL GROUP PCE (%) 
Table 5: Comparison of Reported Group Mean Values of PCE (%) for 7-Methyl-3-octenone-2 Treatment Groups and Historical Group Mean Values of PCE (%) 
for vehicle control (Henderson, 2012) 
Chemical Name  Test system (in vivo)  Test 
object 
No. of 
animals  Route of administration  Dose-levels mg/kg 
bw 
Group mean PCE 
(%) 
Historical group mean range values of (%) PCE 
for the vehicle control group 
7-methyl-3-octenone-
2 
Bone marrow micronucleus 
test  Male rats  6 
Oral gavage 
2 occasions 24 hours apart 
0 42.60 
32.41 - 56.26 
500 39.15 
1000 38.38 
2000 36.85 
Cyclophosphamide 
(positive control) 
Oral gavage 
Once 24 hour before 
sacrifice 
20 46.38 Flavouring Group Evaluation 204
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ABBREVIATIONS 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE    Council of Europe 
DNA   Deoxyribonucleic  acid 
EFSA    The European Food Safety Authority 
EU   European  Union 
FAO    Food and Agriculture Organization of the United Nations  
FGE    Flavouring Group Evaluation  
FISH    Fluorescence In Situ Hybridization 
FLAVIS (FL)  Flavour Information System (database) 
GLP    Good Laboratory Practice 
ID   Identity 
IR   Infrared  Spectroscopy 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
MNBN   MicroNucleated BiNucleate cells 
MS   Masse  Spectra 
MSDI    Maximised Survey-derived Daily Intake 
NMR    Nuclear Magnetic Resonance 
No   Number 
OECD    Organisation for Economic Co-operation and Development 
PCE   PolyChromatic  Erythrocytes 
PHA   PhytoHaemAgglutinin 
(Q)SAR  (Quantitative) Structure Activity Relationship 
RI   Replication  Index 
S9-mix   Rat Liver Metabolic Activation System 
SCF    Scientific Committee on Food 
WHO    World Health Organisation 